NF-κB signalling: Embracing complexity to achieve translation

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 285-291

  Chakraborty, Jayashree Bagchi ^a   Mann, Derek A ^a  

^a The Medical School   (United Kingdom)

Author keywords

c Rel; Fibrosis; Hepatitis; Hepatocellular carcinoma; IKK; NEMO; NF B; p50; p52; Phosphorylation; RelA; RelB; Transcriptional co regulators

Indexed keywords

CRE RECOMBINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE DEACETYLASE 1; I KAPPA B KINASE; I KAPPA B KINASE GAMMA; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN BETA RECEPTOR; PROTEIN P300; PROTEIN P50; PROTEIN P52; PROTEIN SUBUNIT; RANTES; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELB;

ARTICLE; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; DNA BINDING; DRUG TARGETING; FIBROGENESIS; HEPATITIS; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER METABOLISM; MITOSIS; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STEATOSIS; TRANSLATION REGULATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; GENETICS; LIVER; METABOLISM; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; HUMANS; I-KAPPA B KINASE; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEIN BIOSYNTHESIS; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

EID: 75349091256     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.10.030     Document Type: Article

References (67)

1. Elsharkawy A.M., and Mann D.A. Nuclear factor-kappaB and the hepatic inflammation - fibrosis-cancer axis. Hepatology 46 (2007) 590-597
2. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., et al. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11 (2007) 119-132
3. Arkan M.C., Hevener A.L., Greten F.R., Maeda S., Li Z.W., Long J.M., et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11 (2005) 191-198
4. Cai Z., Zhang C., Chang K.S., Jiang J., Ahn B.C., Wakita T., et al. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 79 (2005) 13963-13973
5. Beraza N., Lüdde T., Assmus U., Roskams T., Vander Borght S., and Trautwein C. Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury. Gastroenterology 132 (2007) 2504-2517
6. Geisler F., Algul H., Paxian S., and Schmid R.M. Genetic inactivation of RelA/p65 sensitizes adult mouse hepatocytes to TNF-induced apoptosis in vivo and in vitro. Gastroenterology 132 (2007) 2489-24503
7. Luedde T., Heinrichsdorff J., de Lorenzi R., De Vos R., Roskams T., and Pasparakis M. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci USA 105 (2008) 9733-9738
8. Oakley F., Meso M., Iredale J.P., Green K., Marek C.J., Zhou X., et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 128 (2005) 108-120
9. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
10. Maeda S., Kamata H., Luo J.L., Leffert H., and Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
11. Weber C.K., Liptay S., Wirth T., Adler G., and Schmid R.M. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 119 (2000) 1209-1218
12. Wright M.C., Issa R., Smart D.E., Trim N., Murray G.I., Primrose J.N., et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121 (2001) 685-698
13. Chuang S.E., Cheng A.L., Lin J.K., and Kuo M.L. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 38 (2000) 991-995
14. Choi K.C., Jung M.G., Lee Y.H., Yoon J.C., Kwon S.H., Kang H.B., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res 69 (2009) 583-592
15. Chavez E., Reyes-Gordillo K., Segovia J., Shibayama M., Tsutsumi V., Vergara P., et al. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCl4 treatment in rats. J Appl Toxicol 28 (2009) 35-43
16. Stancovski I., and Baltimore D. NF-kappaB activation: the I kappaB kinase revealed?. Cell 91 (1997) 299-302
17. Jonsson J.R., Clouston A.D., Ando Y., Kelemen L.I., Horn M.J., Adamson M.D., et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121 (2001) 148-155
18. Schreck R., Meier B., Männel D.N., Dröge W., and Baeuerle P.A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 175 (1992) 1181-1194
19. Perkins N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev 8 (2007) 49-62
20. de-Blanco E.J., Pandit B., Hu Z., Shi J., Lewis A., and Li P.K. Inhibitors of NF-kappaB derived from thalidomide. Bioorg Med Chem Lett 17 (2007) 6031-6035
21. Anan A., Baskin-Bey E.S., Isomoto H., Mott J.L., Bronk S.F., Albrecht J.H., et al. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse. Am J Physiol Gastrointest Liver Phys 291 (2006) G709-G716
22. May M.J., D'Acquisto F., Madge L.A., Glöckner J., Pober J.S., and Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289 (2000) 1550-1554
23. Helmberg A., Auphan N., Caelles C., and Karin M. Glucocorticoidinduced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 14 (1995) 452-460
24. Kawamura I., Morishita R., Tsujimoto S., Manda T., Tomoi M., Tomita N., et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaBbinding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Ther 8 (2001) 905-912
25. Trejo-Avila L., Elizondo-González R., Trujillo-Murillo Kdel C., Zapata-Benavides P., Rodríguez-Padilla C., and Rivas-Estilla A.M. Antiviral therapy: inhibition of hepatitis C virus expression by RNA interference directed against the NS5B region of the viral genome. Ann Hepatol 6 (2007) 174-180
26. Luedde T., Assmus U., Wustefeld T., Meyer zu Vilsendorf A., Roskams T., Schmidt-Supprian M., et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 115 (2005) 849-859
27. Ghosh S., and Hayden M.S. New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8 (2008) 837-848
28. Vallabhapurapu S., and Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27 (2009) 693-733
29. Perkins N.D. Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25 (2006) 6717-6730
30. Zhong H., May M.J., Jimi E., and Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9 (2002) 625-636
31. Beg A.A., Sha W.C., Bronson R.T., and Baltimore D. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice. Genes Dev 9 (1995) 2736-2746
32. Li Q., Van Antwerp D., Mercurio F., Lee K.F., and Verma I.M. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science 284 (1999) 321-325
33. Tanaka M., Fuentes M.E., Yamaguchi K., Durnin M.H., Dalrymple S.A., Hardy K.L., et al. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 10 (1999) 421-429
34. Rudolph D., Yeh W.C., Wakeham A., Rudolph B., Nallainathan D., Potter J., et al. Severe liver degeneration and lack of NF-kappaB activation in NEMO/IKKgamma-deficient mice. Genes Dev 14 (2000) 854-862
35. Vainer G.W., Pikarsky E., and Ben-Neriah Y. Contradictory functions of NF-kappaB in liver physiology and cancer. Cancer Lett 267 (2008) 182-188
36. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 19 (2009) 404-413
37. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15 (2009) 283-293
38. Beraza N., Malato Y., Vander Borght S., Liedtke C., Wasmuth H.E., Dreano M., et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis. Gut 57 (2008) 655-663
39. Irelan J.T., Murphy T.J., DeJesus P.D., Teo H., Xu D., Gomez-Ferreria M.A., et al. A role for IkappaB kinase 2 in bipolar spindle assembly. Proc Natl Acad Sci USA 104 (2007) 16940-16945
40. Oakley F., Mann J., Nailard S., Smart D.E., Mungalsingh N., Constandinou C., et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol 166 (2005) 695-708
41. Xu Y., Josson S., Fang F., Oberley T.D., St Clair D.K., Wan X.S., et al. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 69 (2009) 3267-3271
42. Zhou H.J., Pham L.V., Tamayo A.T., Lin-Lee Y.C., Fu L., Yoshimura L.C., et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood 110 (2007) 2121-2127
43. O'Neil B.H., Bůzková P., Farrah H., Kashatus D., Sanoff H., Goldberg R.M., et al. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 72 (2007) 97-104
44. Gieling RG, Elsharkawy AM, Caamano JH, Cowie DE, Wright MC, Ebrahimkhani MR, et al. The c-Rel subunit of nuclear factor-kB regulates liver inflammation, wound-healing and hepatocyte proliferation. Hepatology, in press..
45. Ruddell R.G., Knight B., Tirnitz-Parker J.E., Akhurst B., Summerville L., Subramaniam V.N., et al. Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. Hepatology 49 (2009) 227-239
46. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 16 (2009) 295-308
47. Zhong H., Voll R.E., and Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1 (1998) 661-671
48. Vermeulen L., De Wilde G., Van Damme P., Vanden Berghe W., and Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22 (2003) 1313-1324
49. Arun P., Brown M.S., Ehsanian R., Chen Z., and Van Waes C. Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15 (2009) 5974-5984
50. Mackay H., Hedley D., Major P., Townsley C., Mackenzie M., Vincent M., et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 11 (2005) 5526-5533
51. Dong J., Jimi E., Zhong H., Hayden M.S., and Ghosh S. Repression of gene expression by unphosphorylated NF-kappaB p65 through epigenetic mechanisms. Genes Dev 22 (2008) 1159-1173
52. Mattioli I., Sebald A., Bucher C., Charles R.P., Nakano H., Doi T., et al. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. J Immunol 172 (2004) 6336-6344
53. Sasaki C.Y., Barberi T.J., Ghosh P., and Longo D.L. Phosphorylation of RelA/p65 on serine 536 defines an IκBα-independent NF-κB pathway. J Biol Chem 280 (2005) 34538-43457
54. Lawrence T., Bebien M., Liu G.Y., Nizet V., and Karin M. IKKalpha limits macrophage NF-kappaB activation and to the resolution of inflammation. Nature 434 (2005) 1138-1143
55. Sakurai H., Chiba H., Miyoshi H., Sugita T., and Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274 (1999) 30353-30356
56. Oakley F., Teoh V., Ching-A-Sue G., Bataller R., Colmenero J., Jonsson J.R., et al. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136 (2009) 2334-2344
57. Schwabe R.F., Schnabl B., Kweon Y.O., and Brenner D.A. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 166 (2001) 6812-6819
58. Adli M., and Baldwin A.S. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 281 (2006) 26976-26984
59. Takada Y., Singh S., and Aggarwal B.B. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 279 (2004) 15096-15104
60. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., et al. P50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66 (2006) 11432-11440
61. Cao S., Zhang X., Edwards J.P., and Mosser D.M. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 281 (2006) 26041-26050
62. Wessells J., Baer M., Young H.A., Claudio E., Brown K., Siebenlist U., et al. BCL-3 and NF-kappaB p50 attenuate lipopolysaccharide-induced inflammatory responses in macrophages. J Biol Chem 279 (2004) 49995-50003
63. Carmody R.J., Ruan Q., Palmer S., Hilliard B., and Chen Y.H. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 317 (2007) 675-678
64. Leung T.H., Hoffmann A., and Baltimore D. One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimmers. Cell 118 (2004) 453-464
65. Ogushi I., Iimuro Y., Seki E., Son G., Hirano T., Hada T., et al. Nuclear factor kappa B decoy oligodeoxynucleotides prevent endotoxin-induced fatal liver failure in a murine model. Hepatology 38 (2003) 335-344
66. Nelson D.E., Ihekwaba A.E., Elliott M., Johnson J.R., Gibney C.A., Foreman B.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306 (2004) 704-708
67. Ashall L., Horton C.A., Nelson D.E., Paszek P., Harper C.V., Sillitoe K., et al. Pulsatile stimulation determines timing and specificity of NF-kappaB-dependent transcription. Science 324 (2009) 242-246